Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Qi J, Li M, Wang L, Hu Y, Liu W, Long Z, et al. National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health. 2023;8:e943–55.

Article  PubMed  Google Scholar 

Shaib Y, Davila J, Naumann C, et al. The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. population-based study. Am J Gastroenterol. 2007;102:1377–82.

Article  PubMed  Google Scholar 

Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118:2674–81.

Article  PubMed  Google Scholar 

Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–62.

Article  PubMed  Google Scholar 

Weichselbaum RP, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.

Article  CAS  PubMed  Google Scholar 

Hashimoto D, Satoi S, Fujii T, Sho M, He J, Hackert T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto. Pancreatology. 2023;23:682–8.

Article  PubMed  Google Scholar 

Damanakis AI, Ostertag L, Waldschmidt D, Kütting F, Quaas A, Plum P, et al. Proposal for a definition of oligometastatic disease in pancreatic cancer. BMC Cancer. 2019;19:1261.

Article  PubMed  PubMed Central  Google Scholar 

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393:2051–8.

Article  PubMed  Google Scholar 

Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38:2830–8.

Article  PubMed  PubMed Central  Google Scholar 

Francolini G, Gaetano Allegra A, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561–8.

Article  CAS  PubMed  Google Scholar 

Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2023. https://doi.org/10.1016/S0140-6736(23)01857-3.

Article  PubMed  Google Scholar 

Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019;16:123–35.

Article  PubMed  Google Scholar 

Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–101.

Article  PubMed  Google Scholar 

Cloyd JM, Wang H, Egger ME, et al. Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma. JAMA Surg. 2017;152:1048–56.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:2282–2247.

Article  Google Scholar 

Hellman S, Weichselbaum RR, Oligometastases. J Clin Oncol. 1995;13:8–10.

Article  CAS  PubMed  Google Scholar 

Maddipati R, Norgard RJ, Baslan T, et al. MYC levels regulate metastatic heterogeneity in pancreatic adenocarcinoma. Cancer Discov. 2022;12:542–61.

Article  CAS  PubMed  Google Scholar 

Elamir AM, Karalis JD, Sanford NN, Polanco PM, Folkert MR, Porembka MR, et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys. 2022;114:792–802.

Article  PubMed  Google Scholar 

Scorsetti M, Comito T, Franceschini D, Franzese C, Prete MG, D’Alessio A, et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Br J Radiol. 2020;93:20190627.

Article  PubMed  PubMed Central  Google Scholar 

Webking S, Sandoval ML, Chuong MD, Ucar A, Aparo S, De Zarraga F, et al. Ablative 5-fraction stereotactic MRI-guided adaptive radiotherapy for oligometastatic pancreatic adenocarcinoma. Cancer Control. 2023. https://doi.org/10.1177/10732748231219069.

Article  PubMed  PubMed Central  Google Scholar 

Wu L, Lu Y, Chen L, Yue X, Cen C, Zheng C, et al. The effects of radiotherapy on pancreatic ductal adenocarcinoma in patients with liver metastases. Curr Oncol. 2022;29:7912–24.

Article  PubMed  PubMed Central  Google Scholar 

Bruynzeel AME, Lagerwaard FJ. The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol. 2019;18:128–30.

PubMed  PubMed Central  Google Scholar 

Tyagi N, Liang J, Burleson S, et al. Feasibility of ablative stereotactic body radiation therapy of pancreas cancer patients on a 1.5 Tesla magnetic resonance linac system using abdominal compression. Phys Imaging Radiat Oncol. 2021;19:53–9.

Article  PubMed  PubMed Central  Google Scholar 

Bryant JM, Palm RF, Herrera R, et al. Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with 5-fraction ablative stereotactic magnetic resonance image-guided adaptive radiation therapy(A-SMART). Cancer Control. 2023;30:10732748221150228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tringale KR, Tyagi N, Reyngold M, et al. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance linac system. Phys Imaging Radiat Oncol. 2022;24:88–94.

Article  PubMed  PubMed Central  Google Scholar 

Kim H, Olsen JR, Green OL, et al. MR-guided radiation therapy with concurrent gemcitabine/nab-paclitaxel chemotherapy in inoperable pancreatic cancer: a TITE-CRM phase I trial. Int J Radiat Oncol Biol Phys. 2023;115:214–23.

Article  PubMed  Google Scholar 

Chuong MD, Herrera R, Kaiser A, et al. Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer. Front Oncol. 2022;12:888462.

Article  PubMed  PubMed Central  Google Scholar 

Chuong MD, Bryant JM, Herrera R, et al. Dose-escalated magnetic resonance image-guided abdominopelvic reirradiation with continuous intrafraction visualization, soft tissue tracking, and automatic beam gating. Adv Radiat Oncol. 2021;7:100840.

Article  PubMed  PubMed Central  Google Scholar 

Chuong MD, Bryant J, Mittauer KE, et al. Ablative 5-fraction stereotactic magnetic resonance guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer. Pract Radiat Oncol. 2021;11:134–47.

Article  PubMed  Google Scholar 

Bordeau K, Michalet M, Keskes A, et al. Stereotactic MR-guided adaptive radiotherapy for pancreatic tumors: updated results of the Montpellier prospective registry study. Cancers (Basel). 2022;15:7.

Article  PubMed  Google Scholar 

Michalet M, Bordeau K, Cantaloube M, et al. Stereotactic MR-guided radiotherapy for pancreatic tumors: dosimetric benefit of adaptation and first clinical results in a prospective registry study. Front Oncol. 2022;12:842402.

Article  PubMed